Nanotechnology and COVID-19: quo vadis?

被引:7
|
作者
Tavares, Joao Lima [1 ,2 ]
Cavalcanti, Iago Dillion Lima [1 ,2 ]
Santos Magalhaes, Nereide Stela [1 ]
Lira Nogueira, Mariane Cajuba de Britto [1 ,2 ]
机构
[1] Univ Fed Pernambuco UFPE, Lab Imunopatol Keizo Asami LIKA, Av Prof Moraes Rego,Cidade Univ, BR-12355067 Recife, PE, Brazil
[2] Univ Fed Pernambuco CAV UFPE, Ctr Acad Vitoria, Lab Nanotecnol Biotecnol & Cultura Celulas, Recife, PE, Brazil
关键词
COVID-19; Nanomedicine; Nanocarriers; Liposomes; Nanoparticles; DRUG-DELIVERY; VACCINE; CHALLENGES;
D O I
10.1007/s11051-022-05452-0
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The pandemic COVID-19 has worried everyone due to the high mortality rate and the high number of people hospitalized with severe acute respiratory syndrome caused by SARS-CoV-2. Given the seriousness of this disease, several companies and research institutions have sought alternative treatment and/or prevention methods for COVID-19. Due to its versatility, nanotechnology has allowed the development of protective equipment and vaccines to prevent the disease and reduce the number of severe COVID-19 cases. Thus, this article combined the main works and products developed in a nanotechnological field for COVID-19. We performed a literature search using the keywords "COVID-19," "SARS-CoV-2," "nanoparticles," "nanotechnology," and "liposomes" in the SciELO, Scifinder, PubMed, Sciencedirect, ClinicalTrials, and Nanotechnology Products databases Database. The data survey indicated 48 articles, 62 products, and 32 patents. The use of nanotechnology against COVID-19 has brought benefits in several parameters of this disease, helping develop rapid diagnostic tests that release the result in 10 min, as well as developing vaccines containing genetic material from SARS-CoV-2 (DNA, mRNA, and protein subunits). Nanotechnology is an exceptional ally against COVID-19, contributing to the most diverse areas, helping both prevent, diagnose, and treat COVID-19.
引用
收藏
页数:22
相关论文
共 50 条
  • [21] Quo vadis NOTES?Quo vadis NOTES?
    G. O. Spaun
    L. L. Swanström
    European Surgery, 2008, 40 (5) : 211 - 219
  • [22] Quo vadis Alzheimer?Quo vadis Alzheimer?
    Frank Jessen
    Christian Haass
    Der Nervenarzt, 2019, 90 (9) : 881 - 883
  • [23] Cardiology after COVID-19: Quo Vademus?
    Cannata, Antonio
    Bromage, Daniel, I
    McDonagh, Theresa
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2020, 6 (03) : 208 - 209
  • [24] Covid-19-Pandemic: Forecast Quo vadis SARS-CoV-2?
    Klein, Friederike
    GESUNDHEITSWESEN, 2021, 83 (08/09) : 574 - 574
  • [25] Quo vadis, city? Residents' perception of the lockdown during the first wave of the COVID-19 pandemic in two districts in Rome
    Rogatka, Krzysztof
    Kustra-Rogatka, Aleksandra
    JOURNAL OF URBAN AFFAIRS, 2023,
  • [26] COVID-19: No longer status quo for the surgeon
    John, J.
    Kesner, K.
    SOUTH AFRICAN JOURNAL OF SURGERY, 2020, 58 (02) : 53 - 54
  • [27] Facharztweiterbildung quo vadis?Specialist training quo vadis?
    M. Krusche
    P. Sewerin
    A. Kleyer
    J. Mucke
    D. Vossen
    H. Morf
    Zeitschrift für Rheumatologie, 2019, 78 (8) : 692 - 697
  • [28] Gesundheitspolitik—quo vadis?Health policy—quo vadis?
    G. Neubauer
    Der Onkologe, 2004, 10 (Suppl 2): : S73 - S76
  • [29] Quo vadis, Allgemeinmedizin?Quo vadis, general medicine?
    Armin Mainz
    Zeitschrift für Allgemeinmedizin, 2025, 101 (3): : 155 - 156
  • [30] Transplantationspathologie: Quo vadis?Transplant pathology: Quo vadis?
    H.A. Baba
    G.C. Sotiropoulos
    Der Pathologe, 2011, 32 (2): : 93 - 94